Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Analysts have a mixed outlook, with many maintaining a hold stance due to weak global demand and rising competition. Recent earnings showed revenue improvement but falling margins. The sector remains sluggish, and recovery is only expected in the second half of 2025. Although insider ownership is high and long-term prospects are solid, short-term performance is likely to remain weak, so caution is recommended.
ViTrox is in a short-term uptrend with strong technical signals and rising volume. However, analysts expect limited upside, with a 12-month target around RM 3.05, below the current price. Momentum is strong, but mid-term caution is advised.
